The first-in-human (FIH) study of FCN-159 in melanoma (FCN-159-001) (Si et al., 2019) and a phase I/II trial in NF1 (FCN-159-002) (Hu et al., 2022) demonstrated promising anti-tumor effects and tolerability in adult patients with NRAS mutant solid tumors. This evidence concerns the gene NF1 and neoplasm.